tetano
Editor, Senior Moderator
Sci Rep
. 2024 Jun 11;14(1):13417.
doi: 10.1038/s41598-024-64414-9. Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection
Mariam Movsisyan[SUP] 1 2 [/SUP], Nune Truzyan[SUP] 2 [/SUP], Irina Kasparova[SUP] 3 [/SUP], Armine Chopikyan[SUP] 2 4 [/SUP], Ra'ed Sawaqed[SUP] 5 [/SUP], Alexandra Bedross[SUP] 5 [/SUP], Meline Sukiasyan[SUP] 1 2 [/SUP], Karen Dilbaryan[SUP] 2 [/SUP], Sanobar Shariff[SUP] 5 [/SUP], Burhan Kwantala[SUP] 2 [/SUP], Gohar Hakobjanyan[SUP] 2 6 [/SUP], Gayane Petrosyan[SUP] 2 6 [/SUP], Armine Hakobyan[SUP] 1 [/SUP], Konstantin Yenkoyan[SUP] 7 8 [/SUP]
Affiliations
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that gave rise to COVID-19 infection produced a worldwide health crisis. The virus can cause a serious or even fatal disease. Comprehending the complex immunological responses triggered by SARS-CoV-2 infection is essential for identifying pivotal elements that shape the course of the disease and its enduring effects on immunity. The span and potency of antibody responses provide valuable perspicuity into the resilience of post-infection immunity. The analysis of existing literature reveals a diverse controversy, confining varying data about the persistence of particular antibodies as well as the multifaceted factors that impact their development and titer, Within this study we aimed to understand the dynamics of anti-SARS-CoV-2 antibodies against nucleocapsid (anti-SARS-CoV-2 (N)) and spike (anti-SARS-CoV-2 (N)) proteins in long-term immunity in convalescent patients, as well as the factors influencing the production and kinetics of those antibodies. We collected 6115 serum samples from 1611 convalescent patients at different post-infection intervals up to 21 months Study showed that in the fourth month, the anti-SARS-CoV-2 (N) exhibited their peak mean value, demonstrating a 79% increase compared to the initial month. Over the subsequent eight months, the peak value experienced a modest decline, maintaining a relatively elevated level by the end of study. Conversely, anti-SARS-CoV-2 (S) exhibited a consistent increase at each three-month interval over the 15-month period, culminating in a statistically significant peak mean value at the study's conclusion. Our findings demonstrate evidence of sustained seropositivity rates for both anti-SARS-CoV-2 (N) and (S), as well as distinct dynamics in the long-term antibody responses, with anti-SARS-CoV-2 (N) levels displaying remarkable persistence and anti-SARS-CoV-2 (S) antibodies exhibiting a progressive incline.
Keywords: Anti-SARS-CoV-2 (N); Anti-SARS-CoV-2 (S); Kinetics; Long-term humoral immunity.
. 2024 Jun 11;14(1):13417.
doi: 10.1038/s41598-024-64414-9. Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection
Mariam Movsisyan[SUP] 1 2 [/SUP], Nune Truzyan[SUP] 2 [/SUP], Irina Kasparova[SUP] 3 [/SUP], Armine Chopikyan[SUP] 2 4 [/SUP], Ra'ed Sawaqed[SUP] 5 [/SUP], Alexandra Bedross[SUP] 5 [/SUP], Meline Sukiasyan[SUP] 1 2 [/SUP], Karen Dilbaryan[SUP] 2 [/SUP], Sanobar Shariff[SUP] 5 [/SUP], Burhan Kwantala[SUP] 2 [/SUP], Gohar Hakobjanyan[SUP] 2 6 [/SUP], Gayane Petrosyan[SUP] 2 6 [/SUP], Armine Hakobyan[SUP] 1 [/SUP], Konstantin Yenkoyan[SUP] 7 8 [/SUP]
Affiliations
- PMID: 38862731
- PMCID: PMC11167004
- DOI: 10.1038/s41598-024-64414-9
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that gave rise to COVID-19 infection produced a worldwide health crisis. The virus can cause a serious or even fatal disease. Comprehending the complex immunological responses triggered by SARS-CoV-2 infection is essential for identifying pivotal elements that shape the course of the disease and its enduring effects on immunity. The span and potency of antibody responses provide valuable perspicuity into the resilience of post-infection immunity. The analysis of existing literature reveals a diverse controversy, confining varying data about the persistence of particular antibodies as well as the multifaceted factors that impact their development and titer, Within this study we aimed to understand the dynamics of anti-SARS-CoV-2 antibodies against nucleocapsid (anti-SARS-CoV-2 (N)) and spike (anti-SARS-CoV-2 (N)) proteins in long-term immunity in convalescent patients, as well as the factors influencing the production and kinetics of those antibodies. We collected 6115 serum samples from 1611 convalescent patients at different post-infection intervals up to 21 months Study showed that in the fourth month, the anti-SARS-CoV-2 (N) exhibited their peak mean value, demonstrating a 79% increase compared to the initial month. Over the subsequent eight months, the peak value experienced a modest decline, maintaining a relatively elevated level by the end of study. Conversely, anti-SARS-CoV-2 (S) exhibited a consistent increase at each three-month interval over the 15-month period, culminating in a statistically significant peak mean value at the study's conclusion. Our findings demonstrate evidence of sustained seropositivity rates for both anti-SARS-CoV-2 (N) and (S), as well as distinct dynamics in the long-term antibody responses, with anti-SARS-CoV-2 (N) levels displaying remarkable persistence and anti-SARS-CoV-2 (S) antibodies exhibiting a progressive incline.
Keywords: Anti-SARS-CoV-2 (N); Anti-SARS-CoV-2 (S); Kinetics; Long-term humoral immunity.